Eisai Bets On Accelerated Approval For Biogen-Partnered Lecanemab
Filing Before Pivotal Data Beats Lilly’s Pre-Phase III Submission
Following Biogen’s lead with Aduhelm, the first disease-modifying Alzheimer’s therapy approved in the US, Eisai began a rolling BLA submission for lecanemab (BAN2401) ahead of next year’s Phase III results.
